Sector News

UCB enters drug discovery collaboration with Aitia

March 19, 2023
Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia.

The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

It will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing new therapies discovery for Huntington’s disease patients.

UCB executive vice-president and chief scientific officer Dhaval Patel said: “We are pleased to work with Aitia in a bid to unravel the circuity of this debilitating disease.

“We see this collaboration as an investment in next-generation science and technology, allowing us to accelerate our understanding of human pathobiology and explore the potential of developing novel medicines through AI.”

According to the company, Huntington’s disease affects nearly one in 10,000 people across the world.

At present, there is no cure for the disease, with limited treatment options.

Aitia CEO and co-founder Colin Hill said: “At Aitia, our mission is to discover the next generation of breakthrough drugs to improve outcomes for patients where there is a high unmet need.

“We believe that Huntington’s disease is overdue for major disruption and breakthroughs from our Gemini Digital Twins which are created from large quantities of multi-omic patient data and causal AI.

“We’re excited to collaborate closely with UCB to gain deeper insights into the underlying mechanisms of this complex disease and hope to drive major advancements in drug discovery and development faster than ever before.”

The company is exposing the hidden biological mechanisms of disease for developing Digital Twins of disease in immunology, neurodegenerative disorders, and oncology by using the convergence of multi-omic patient data, causal learning and AI and high-performance computing.

Source: pharmaceutical-technology.com

 

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach